Measurable Residual Disease - What does it mean to be MRD Positive

Measurable Residual Disease - What does it mean to be MRD Positive

cancergrace

6 months
159 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
GRACE - Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL). This panel consisted of Drs. Elias Jabbour, MD, (Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas), Joseph D. Khoury, MD, (Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas), and Aaron C. Logan, MD, PhD, (Associate Professor Division of Hematology and Blood and Marrow Transplantation at the University of California, San Francisco). In this video, the doctors discuss what it means to be MRD positive. For more information visit GRACE at https://cancerGRACE.org, or CCO at https://www.clinicaloptions.com/oncol....
Up Next Autoplay
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
0 Views
cancernewsupdate 9 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 33 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 37 minutes
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
1 Views
ash 13 hours
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 13 hours
Brentuximab Vedotin with Chemotherapy #ASH19
Brentuximab Vedotin with Chemotherapy #ASH19
Category: Chronic Myelogenous Leukemia
0 Views
ash 19 hours
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
4 Views
ash 21 hours
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 22 hours
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours